NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
QCOM
QUALCOMM Incorporated
QCOM has a slight edge over NVO overall, supported by stronger valuation.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
QCOM Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Healthy | |
| Healthy |
QCOM's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over QCOM in the historical PE scenario, which offers more potential upside but is not a forecast.
QCOM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $175 | -1.1% |
| Current | 14x | $177 | — |
| Fair | 20x | $248 | +40% |
| Expensive | 26x | $333 | +88% |
Historical ranges are pointers, not guarantees.
QCOM's PE is in its cheap range at 14x.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
QCOM Forward outlook
There aren't enough analyst estimates for QCOM to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over QCOM on earnings, with more consistent year-over-year improvement.
QCOM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $12.70 | +153% |
| Q2 2026 | $8.76 | -15% |
| Q1 2026 | $9.32 | -4.9% |
| Q4 2025 | $4.96 | -47% |
| Q3 2025 | $5.01 | -44% |
| Q2 2025 | $10.35 | +34% |
| Q1 2025 | $9.80 | +32% |
| Q4 2024 | $9.34 | +35% |
QCOM earned $12.70 per share over the past year, up 153% from the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over QCOM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over QCOM on profitability, with a higher operating margin.
QCOM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.3B | -8.4% |
| Q2 2026 | $9.9B | -4% |
| Q1 2026 | $10.6B | -3.5% |
| Q4 2025 | $12.3B | +5% |
| Q3 2025 | $11.3B | +10% |
| Q2 2025 | $10.4B | +10% |
| Q1 2025 | $11B | +17% |
| Q4 2024 | $11.7B | +17% |
QCOM's revenue grew through 2024 and has held roughly level since: $10.3B last quarter, down 8.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 13% | -13 points |
| Q2 2026 | 16% | -10 points |
| Q1 2026 | 22% | -6.6 points |
| Q4 2025 | 27% | -3 points |
| Q3 2025 | 26% | +0.7 points |
| Q2 2025 | 27% | +3 points |
| Q1 2025 | 28% | +3.5 points |
| Q4 2024 | 30% | +1 points |
QCOM's operating margin was 13% last quarter, down 13 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over QCOM on cash flow, with more consistent year-over-year improvement.
QCOM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.8B | -49% |
| Q2 2026 | $495M | -81% |
| Q1 2026 | $1.9B | -18% |
| Q4 2025 | $4.4B | +2.5% |
| Q3 2025 | $3.6B | +50% |
| Q2 2025 | $2.6B | -3.2% |
| Q1 2025 | $2.3B | -31% |
| Q4 2024 | $4.3B | +58% |
QCOM's free cash flow has been positive every quarter for seven years: $8.7B over the past year, down 33% from the year before.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over QCOM on leverage, with a lower net debt burden relative to earnings.
QCOM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.0x | Healthy |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 0.7x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
QCOM's net debt is about a year of its operating earnings (EBITDA), up from less than a year a year ago.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
QCOM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 40.2 | Neutral |
QCOM's weekly RSI is 51 (neutral) and its Stochastic is 40 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO has the edge over QCOM on valuation relative to its sector.
QCOM PE vs Technology Sector
| Metric | QCOM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 28x | 50% below |
| PE % | 17 | 35 | 18 pts below |
QCOM is trading at 14x earnings, a 50% discount to the Technology sector's median of 28x.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
QCOM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $177.2 | 0% below |
| 20 week MA | $172.8 | 2.5% above |
| 50 week MA | $170.7 | 3.8% above |
| 100 week MA | $164.3 | 7.8% above |
| 200 week MA | $155.1 | 14% above |
QCOM has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
QCOM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $88.8 | $148.8 | +68% |
| 2021 | $148.8 | $182.7 | +23% |
| 2022 | $182.7 | $110.8 | -39% |
| 2023 | $110.8 | $144.6 | +30% |
| 2024 | $144.6 | $157.2 | +8.7% |
| 2025 | $157.2 | $174.8 | +11% |
| 2026 YTD | $174.8 | $177.1 | +1.3% |
QCOM has the edge over NVO on returns for 2026, with the stronger performance.